NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis $13.98 +0.14 (+1.01%) Closing price 04:00 PM EasternExtended Trading$13.84 -0.15 (-1.04%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Dynavax Technologies Stock (NASDAQ:DVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dynavax Technologies alerts:Sign Up Key Stats Today's Range$13.74▼$14.0150-Day Range$12.39▼$14.4052-Week Range$9.74▼$14.63Volume1.54 million shsAverage Volume2.00 million shsMarket Capitalization$1.73 billionP/E Ratio77.67Dividend YieldN/APrice Target$21.50Consensus RatingHold Company OverviewDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More… Remove Ads Dynavax Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreDVAX MarketRank™: Dynavax Technologies scored higher than 91% of companies evaluated by MarketBeat, and ranked 75th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingDynavax Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDynavax Technologies has only been the subject of 3 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth53.13% Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 77.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 77.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.55.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.85% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.59 Percentage of Shares Shorted14.85% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.47 News SentimentDynavax Technologies has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dynavax Technologies this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Stock News HeadlinesWall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?March 12, 2025 | msn.comDeep Track Capital sends letter to Dynavax Technologies’ boardMarch 11, 2025 | markets.businessinsider.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.March 25, 2025 | Stansberry Research (Ad)Deep Track Capital Sends Letter to Dynavax Technologies’ Board of DirectorsMarch 10, 2025 | finance.yahoo.comDynavax to execute debt refinancingMarch 6, 2025 | seekingalpha.comDynavax Technologies Corp Announces Convertible Debt Refinancing and Stock RepurchaseMarch 6, 2025 | gurufocus.comDynavax Announces Convertible Debt Refinancing and Common Stock Share RepurchaseMarch 6, 2025 | prnewswire.comIs Dynavax Technologies Corporation (DVAX) the Best Small Cap Pharma Stock to Buy Now?March 2, 2025 | insidermonkey.comSee More Headlines DVAX Stock Analysis - Frequently Asked Questions How have DVAX shares performed this year? Dynavax Technologies' stock was trading at $12.77 at the beginning of 2025. Since then, DVAX stock has increased by 9.5% and is now trading at $13.98. View the best growth stocks for 2025 here. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Thursday, February, 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The biopharmaceutical company had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a trailing twelve-month return on equity of 4.22% and a net margin of 9.85%. Who are Dynavax Technologies' major shareholders? Top institutional investors of Dynavax Technologies include Deep Track Capital LP (13.53%), Vanguard Group Inc. (6.97%), Chicago Capital LLC (4.09%) and Deerfield Management Company L.P. Series C (3.95%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings2/20/2025Today3/25/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees350Year Founded1996Price Target and Rating Average Stock Price Target$21.50 High Stock Price Target$31.00 Low Stock Price Target$12.00 Potential Upside/Downside+53.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio77.67 Forward P/E Ratio43.69 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins9.85% Pretax Margin9.29% Return on Equity4.22% Return on Assets2.67% Debt Debt-to-Equity Ratio0.33 Current Ratio13.23 Quick Ratio12.34 Sales & Book Value Annual Sales$277.25 million Price / Sales6.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book2.91Miscellaneous Outstanding Shares124,071,000Free Float127,538,000Market Cap$1.73 billion OptionableOptionable Beta1.23 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:DVAX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.